Mexiletine block of wild‐type and inactivation‐deficient human skeletal muscle hNav1.4 Na+ channels
Authors:
Open Access
- 3 February 2004
- journal article
- research article
- Published by Wiley in The Journal of Physiology
- Vol. 554 (3) , 621-633
Abstract
Mexiletine is a class 1b antiarrhythmic drug used for ventricular arrhythmias but is also found to be effective for paramyotonia congenita, potassium-aggravated myotonia, long QT–3 syndrome, and neuropathic pain. This drug elicits tonic block of Na+ channels when cells are stimulated infrequently and produces additional use-dependent block during repetitive pulses. We examined the state-dependent block by mexiletine in human skeletal muscle hNav1.4 wild-type and inactivation-deficient mutant Na+ channels (hNav1.4-L443C/A444W) expressed in HEK293t cells with a β1 subunit. The 50% inhibitory concentrations (IC50) for the inactivated-state block and the resting-state block of wild-type Na+ channels by mexiletine were measured as 67.8 ± 7.0 μm and 431.2 ± 9.4 μm, respectively (n= 5). In contrast, the IC50 for the block of open inactivation-deficient mutant channels at +30 mV by mexiletine was 3.3 ± 0.1 μm (n= 5), which was within the therapeutic plasma concentration range (2.8–11 μm). Estimated on- and off-rates for the open-state block by mexiletine at +30 mV were 10.4 μm−1 s−1 and 54.4 s−1, respectively. Use-dependent block by mexiletine was greater in inactivation-deficient mutant channels than in wild-type channels during repetitive pulses. Furthermore, the IC50 values for the block of persistent late hNav1.4 currents in chloramine-T-pretreated cells by mexiletine was 7.5 ± 0.8 μm (n= 5) at +30 mV. Our results together support the hypothesis that the in vivo efficacy of mexiletine is primarily due to the open-channel block of persistent late Na+ currents, which may arise during various pathological conditions.Keywords
This publication has 25 references indexed in Scilit:
- Tryptophan Scanning of D1S6 and D4S6 C-Termini in Voltage-Gated Sodium ChannelsBiophysical Journal, 2003
- Mexiletine block of disease-associated mutations in S6 segments of the human skeletal muscle Na+ channelThe Journal of Physiology, 2001
- Late Sodium Current is a Novel Target for Amiodarone: Studies in Failing Human MyocardiumJournal of Molecular and Cellular Cardiology, 2001
- Pharmacological targeting of long QT mutant sodium channels.Journal of Clinical Investigation, 1997
- Paramyotonia congenita: Abnormal short exercise test, and improvement after mexiletine therapyMuscle & Nerve, 1994
- Functional expression of sodium channel mutations identified in families with periodic paralysisNeuron, 1993
- The Use of Oral Mexiletine for the Treatment of Pain after Peripheral Nerve InjuryAnesthesiology, 1992
- Inhibition of sodium currents by local anesthetics in chloramine-T-treated squid axons. The role of channel activation.Journal of General Physiology, 1987
- Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channelsBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1977
- Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction.Journal of General Physiology, 1977